There was also a significant decrease in survival time following hormone treatment with increased expression of either EGFR or Her-2/Neu.[79] While the data suggests there is some variation in the significance of growth factor signaling in prostate cancer, a growing body of evidence supports the hypothesis that it is likely to be important in progression to hormone independence. Here, ERBB2 is linked to prostate carcinoma.